对中国3429例羊膜腔穿刺样本应用拷贝数变异测序进行的前瞻性染色体分析
这项前瞻性研究对3429例因高龄、母血清筛查高风险或超声软指标阳性行羊膜腔穿刺的孕妇,用分辨率0.1 Mb的拷贝数变异测序检测胎儿染色体异常,全部样本获可判读结果,致病/可能致病变异累计频率2.83%,意义不明变异1.43%,测序较核型分析多检出1%的致病/可能致病变异。
要点
- 3429例羊水样本全部获得可判读的拷贝数变异测序结果,96%为正常分子核型、4%为异常分子核型。
- 共检出146处胎儿染色体异常,致病/可能致病变异累计频率2.83%,意义不明变异1.43%。
- 高龄、母血清筛查高风险及超声软指标三组中最多见的全染色体非整倍体为21三体。
核心结论
- 在这项大型前瞻性临床研究中,拷贝数变异测序对产前样本中具有临床意义的胎儿异常表现出高可靠性和准确性。
- 基于关键性能指标,拷贝数变异测序似乎是适合对存在疑似胎儿染色体异常风险的一般人群孕妇进行一线诊断的方法。
研究设计与样本
- 前瞻性分析,纳入3429例因不同风险指征(包括高龄、母血清筛查高风险和超声软指标阳性)转诊行羊膜腔穿刺及胎儿染色体检测的孕妇。
- 羊膜腔穿刺按标准程序进行,羊水细胞DNA以分辨率0.1 Mb的拷贝数变异测序分析。
- 胎儿染色体异常(包括全染色体非整倍体和片段性失衡)由金标准细胞遗传学和分子方法独立确认,致病性按美国医学遗传学与基因组学学会序列变异指南判定。
主要发现
- 全部3429例羊膜腔穿刺样本均获得清晰可判读的拷贝数变异测序结果。
- 拷贝数变异测序识别3293例(96%)分子核型正常、136例(4%)分子核型异常。
- 共检出146处胎儿染色体异常,包括46处全染色体非整倍体(致病)、29处与染色体疾病综合征有已知或疑似关联的亚显微微缺失/微重复(致病)、22处其他微缺失/微重复(可能致病)和49处意义不明变异。
- 该患者队列中致病/可能致病变异和意义不明变异染色体异常的累计频率分别为2.83%和1.43%。
- 在高龄、母血清筛查高风险和超声软指标三个高风险组中,最常见的全染色体非整倍体为21三体,其次为性染色体非整倍体、18三体和13三体。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Next-generation sequencing is emerging as a viable alternative to chromosome microarray analysis for the diagnosis of chromosome disease syndromes. One next-generation sequencing methodology, copy number variation sequencing, has been shown to deliver high reliability, accuracy, and reproducibility for detection of fetal copy number variations in prenatal samples. However, its clinical utility as a first-tier diagnostic method has yet to be demonstrated in a large cohort of pregnant women referred for fetal chromosome testing. OBJECTIVE: We sought to evaluate copy number variation sequencing as a first-tier diagnostic method for detection of fetal chromosome anomalies in a general population of pregnant women with high-risk prenatal indications. STUDY DESIGN: This was a prospective analysis of 3429 pregnant women referred for amniocentesis and fetal chromosome testing for different risk indications, including advanced maternal age, high-risk maternal serum screening, and positivity for an ultrasound soft marker. Amniocentesis was performed by standard procedures. Amniocyte DNA was analyzed by copy number variation sequencing with a chromosome resolution of 0.1 Mb. Fetal chromosome anomalies including whole chromosome aneuploidy and segmental imbalances were independently confirmed by gold standard cytogenetic and molecular methods and their pathogenicity determined following guidelines of the American College of Medical Genetics for sequence variants. RESULTS: Clear interpretable copy number variation sequencing results were obtained for all 3429 amniocentesis samples. Copy number variation sequencing identified 3293 samples (96%) with a normal molecular karyotype and 136 samples (4%) with an altered molecular karyotype. A total of 146 fetal chromosome anomalies were detected, comprising 46 whole chromosome aneuploidies (pathogenic), 29 submicroscopic microdeletions/microduplications with known or suspected associations with chromosome disease syndromes (pathogenic), 22 other microdeletions/microduplications (likely pathogenic), and 49 variants of uncertain significance. Overall, the cumulative frequency of pathogenic/likely pathogenic and variants of uncertain significance chromosome anomalies in the patient cohort was 2.83% and 1.43%, respectively. In the 3 high-risk advanced maternal age, high-risk maternal serum screening, and ultrasound soft marker groups, the most common whole chromosome aneuploidy detected was trisomy 21, followed by sex chromosome aneuploidies, trisomy 18, and trisomy 13. Across all clinical indications, there was a similar incidence of submicroscopic copy number variations, with approximately equal proportions of pathogenic/likely pathogenic and variants of uncertain significance copy number variations. If karyotyping had been used as an alternate cytogenetics detection method, copy number variation sequencing would have returned a 1% higher yield of pathogenic or likely pathogenic copy number variations. CONCLUSION: In a large prospective clinical study, copy number variation sequencing delivered high reliability and accuracy for identifying clinically significant fetal anomalies in prenatal samples. Based on key performance criteria, copy number variation sequencing appears to be a well-suited methodology for first-tier diagnosis of pregnant women in the general population at risk of having a suspected fetal chromosome abnormality.
引用
- Wang J, Chen L, Zhou C, et al. Prospective chromosome analysis of 3429 amniocentesis samples in China using copy number variation sequencing. Am J Obstet Gynecol. 2018. PMID: 29852155. doi:10.1016/j.ajog.2018.05.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。